November 4, 2026

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: Outcome of the Board Meeting held on November 4, 2026

The Board of Directors of the Company at its meeting held today, November 4, 2026, has, inter alia, considered and approved:

a) the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

   We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors.

b) the payment of interim dividend of 700% i.e. Rs.7.00 (Rupees seven only) per equity share of Re.1/- each on the equity share capital of the Company. The Company has fixed November 11, 2026, as the Record Date for the purpose of payment of Interim Dividend and the same will be paid on or before November 20, 2026.

c) the proposal to file a Scheme of Amalgamation for merger of Auroactive Pharma Private Limited, wholly owned subsidiary of the Company with Apitoria Pharma Private Limited, wholly owned subsidiary of the Company, with Hon'ble NCLT, Hyderabad, that has been approved by the Board of Directors of the respective companies.

d) the transfer of ownership of Auro Pharma LLC, Russia, from Auroactive Pharma Private Limited to Auropharm Overseas Limited, wholly owned subsidiaries of the Company that has been approved by the Board of Directors of the respective companies.

e) based on the recommendation of the Nomination and Remuneration/Compensation Committee and subject to the approval of the Members through Postal Ballot, the re-appointment of Mr. Mangalam Ramasubramanian Kumar (DIN 03628755) as a Director (Non-executive and Independent) of the Company for the second term of 5 (five) years with effect from April 1, 2027. His first term as Non-executive and Independent Director is completing on March 31, 2027.

The Board meeting commenced at 4:15 p.m. and concluded at 6:00 p.m.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.11.04 19:30:00 +05'30'

B. Adi Reddy
Company Secretary

Enclosures: as above.

AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)
www.aurobindo.com
Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: info@aurobindo.com

(All amounts are in ₹ million, unless otherwise stated)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A	**Continuing Operations:**						
1	**Revenue from operations**						
	(a) Net sales/ income from operations	**31,627.9**	27,816.9	27,001.0	**59,444.8**	54,709.0	1,08,537.1
	(b) Other operating income	**145.4**	178.2	298.3	**323.6**	558.6	1,163.3
	Total revenue from operations	**31,773.3**	27,995.1	27,299.3	**59,768.4**	55,267.6	1,09,700.4
2	**Other income**						
	(a) Foreign exchange gain (net)	**221.0**	729.9	591.5	**950.9**	997.5	1,790.7
	(b) Others	**807.0**	1,689.0	1,003.7	**2,496.0**	1,435.4	4,084.6
	Total other income	**1,028.0**	2,418.9	1,595.2	**3,446.9**	2,432.9	5,875.3
3	**Total income (1+2)**	**32,801.3**	30,414.0	28,894.5	**63,215.3**	57,700.5	1,15,575.7
4	**Expenses**						
	(a) Cost of materials consumed	**13,809.7**	12,888.9	12,385.1	**26,698.6**	25,740.7	52,200.9
	(b) Purchase of stock-in-trade	**13.5**	-	10.5	**13.5**	10.5	49.0
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	**777.2**	(480.5)	1,054.0	**296.7**	1,430.9	542.4
	(d) Employee benefits expense	**3,000.7**	2,959.1	2,768.2	**5,959.8**	5,447.1	10,943.3
	(e) Finance costs	**480.9**	470.7	574.4	**951.6**	1,174.4	2,130.7
	(f) Depreciation and amortisation expenses	**695.2**	689.9	670.0	**1,385.1**	1,325.9	2,676.0
	(g) Other expenses	**4,314.6**	3,805.1	3,868.2	**8,119.7**	7,482.8	15,037.4
	Total expenses	**23,091.8**	20,333.2	21,330.4	**43,425.0**	42,612.3	83,579.7
5	**Profit before exceptional items and tax from continuing operations (3-4)**	**9,709.5**	10,080.8	7,564.1	**19,790.3**	15,088.2	31,996.0
6	**Exceptional items (refer note 5)**	-	-	-	-	-	173.8
7	**Profit before tax from continuing operations (5-6)**	**9,709.5**	10,080.8	7,564.1	**19,790.3**	15,088.2	31,822.2
8	**Tax expense**						
	Current tax	**2,477.4**	2,715.0	1,744.8	**5,192.4**	3,627.4	7,512.3
	Deferred tax	**(3.7)**	(6.4)	(3.1)	**(10.1)**	29.7	19.6
	Total tax expense	**2,473.7**	2,708.6	1,741.7	**5,182.3**	3,657.1	7,531.9
9	**Profit after tax from continuing operations (7-8)**	**7,235.8**	7,372.2	5,822.4	**14,608.0**	11,431.1	24,290.3
B	**Discontinued Operations: (Refer note 4)**						
10	Loss before tax from discontinued operations	-	-	(11.3)	-	(34.5)	(186.4)
11	Tax expense from discontinued operations	-	-	(2.6)	-	(8.4)	(44.1)
12	**Loss from discontinued operations (10-11)**	-	-	(8.7)	-	(26.1)	(142.3)
13	**Profit after tax (9+12)**	**7,235.8**	7,372.2	5,813.7	**14,608.0**	11,405.0	24,148.0
14	**Other comprehensive income**						
	A) Items that will not to be reclassified subsequently to profit or loss:						
	(a) Re-measurement of defined benefit liability	**(60.4)**	3.6	(0.4)	**(56.8)**	(18.0)	14.5
	(b) Income-tax relating to items that will not be reclassified to profit or loss	**15.2**	(0.9)	0.1	**14.3**	4.5	(3.7)
	B) Items that will be reclassified subsequently to profit or loss:						
	a) Fair value change on derivatives designated as cash flow hedge (net)	**78.0**	-	-	**78.0**	-	-
	b) Income-tax on items that will be reclassified subsequently to profit or loss	**(19.6)**	-	-	**(19.6)**	-	-
	Total other comprehensive income/(loss) (net of tax)	**13.2**	2.7	(0.3)	**15.9**	(13.5)	10.8
15	**Total comprehensive income (13+14)**	**7,249.0**	7,374.9	5,813.4	**14,623.9**	11,391.5	24,158.8
16	Paid-up equity share capital (face value ₹ 1 per share)	**575.4**	575.4	580.8	**575.4**	580.8	580.8
17	Other equity						2,26,596.1
18	Earnings per equity share from continuing operations (face value ₹ 1 per share)	**(Not annualised)**	(Not annualised)	(Not annualised)	**(Not annualised)**	(Not annualised)	(Annualised)
	(a) Basic (in ₹)	**12.58**	12.75	10.02	**25.33**	19.68	41.83
	(b) Diluted (in ₹)	**12.58**	12.75	10.02	**25.33**	19.68	41.83
19	Earnings per equity share from discontinued operations (face value ₹ 1 per share)	**(Not annualised)**	(Not annualised)	(Not annualised)	**(Not annualised)**	(Not annualised)	(Annualised)
	(a) Basic (in ₹)	-	-	(0.01)	-	(0.04)	(0.25)
	(b) Diluted (in ₹)	-	-	(0.01)	-	(0.04)	(0.25)
20	Earnings per equity share for total operations (face value ₹ 1 per share)	**(Not annualised)**	(Not annualised)	(Not annualised)	**(Not annualised)**	(Not annualised)	(Annualised)
	(a) Basic (in ₹)	**12.58**	12.75	10.01	**25.33**	19.64	41.58
	(b) Diluted (in ₹)	**12.58**	12.75	10.01	**25.33**	19.64	41.58

DELOITTE HASKINS & SELLS CHARTERED ACCOUNTANTS

AUROBINDO PHARMA LIMITED HYDERABAD

Standalone Balance Sheet

(All amounts are in ₹ million, unless otherwise stated)

Sl. No.	Particulars	As at 30.09.2026 Unaudited	As at 31.03.2026 Audited
	ASSETS		
1	**Non-current assets**		
	Property, plant and equipment	**23,783.0**	23,177.6
	Capital work-in-progress	**2,240.6**	2,285.5
	Right-of-use assets	**924.9**	1,021.7
	Goodwill	**-**	917.0
	Other intangible assets	**94.4**	321.0
	Financial assets		
	Investments	**1,75,810.7**	1,68,361.5
	Loans	**11,588.6**	12,104.5
	Trade receivables	**-**	-
	Other financial assets	**503.2**	490.4
	Income tax assets (net)	**394.9**	2,902.1
	Other non-current assets	**1,110.1**	993.7
	Total non-current assets	**2,16,450.4**	2,12,575.0
2	**Current assets**		
	Inventories	**24,444.1**	23,605.7
	Financial assets		
	Investments	**0.3**	7,262.0
	Trade receivables	**49,920.3**	42,096.8
	Cash and cash equivalents	**973.9**	1,604.3
	Bank balances other than cash and cash equivalents	**20.3**	20.7
	Loans	**60.5**	56.9
	Other financial assets	**225.6**	32.3
	Other current assets	**6,096.8**	5,540.1
	Total current assets	**81,741.8**	80,218.8
	TOTAL ASSETS (1+2)	**2,98,192.2**	2,92,793.8
	EQUITY AND LIABILITIES		
1	**Equity**		
	Equity share capital	**575.4**	580.8
	Other equity	**2,33,167.3**	2,26,596.1
	Total equity	**2,33,742.7**	2,27,176.9
	Liabilities		
2	**Non-current liabilities**		
	Financial liabilities		
	Lease liabilities	**761.0**	854.1
	Provisions	**659.8**	731.7
	Deferred tax liability (net)	**1,032.8**	1,037.6
	Total non-current liabilities	**2,453.6**	2,623.4
3	**Current liabilities**		
	Financial liabilities		
	Borrowings	**38,893.9**	41,824.7
	Lease liabilities	**199.1**	173.6
	Trade payables		
	total outstanding dues of micro enterprises and small enterprises	**521.8**	782.0
	total outstanding dues of creditors other than micro enterprises and small enterprises	**17,836.6**	17,538.0
	Other financial liabilities	**1,903.6**	1,479.7
	Other current liabilities	**372.4**	412.4
	Provisions	**295.2**	245.8
	Current tax liabilities (net)	**1,973.3**	537.3
	Total current liabilities	**61,995.9**	62,993.5
	TOTAL EQUITY AND LIABILITIES (1+2+3)	**2,98,192.2**	2,92,793.8

DELOITTE HASKINS & SELLS CHARTERED ACCOUNTANTS

AUROBINDO PHARMA LIMITED HYDERABAD

Standalone Statement of Cash Flows

(All amounts are in ₹ million, unless otherwise stated)

Sl. No.	Particulars	For the half year ended 30.09.2026 Unaudited	For the half year ended 30.09.2025 Unaudited
1	**CASH FLOW FROM OPERATING ACTIVITIES**		
	Net profit before tax		
	from continuing operations	**19,790.3**	15,088.2
	from discontinued operations	**-**	(34.5)
	Adjustments for :		
	Depreciation and amortisation expenses	**1,385.1**	1,415.1
	Allowance for expected credit losses (net)	**5.8**	(45.8)
	Unrealised foreign exchange gain (net)	**(1,009.7)**	(1,350.6)
	Profit on sale of property, plant and equipment (net)	**(210.2)**	(7.3)
	Dividend income	**-**	(705.6)
	Profit on sale of investments	**(65.0)**	-
	Finance costs	**943.6**	1,167.1
	Interest income	**(1,648.0)**	(597.4)
	Operating profit before working capital changes	**19,191.9**	14,929.2
	Movements in working capital:		
	(Increase)/decrease in trade receivables	**(7,247.7)**	145.6
	(Increase)/decrease in inventories	**(1,196.5)**	757.3
	(Increase)/decrease in loans	**(3.7)**	(9.0)
	(Increase)/decrease in other financial assets	**(16.9)**	(134.0)
	(Increase)/decrease in other assets	**(700.1)**	2,350.0
	Increase/(decrease) in trade payables	**200.3**	(1,813.3)
	Increase/(decrease) in provision for employee benefits	**41.1**	269.5
	Increase/(decrease) in other financial liabilities	**245.5**	(749.6)
	Increase/(decrease) in other liabilities	**(39.9)**	211.0
	Cash generated from operating activities	**10,474.0**	15,956.7
	Income-tax paid (net)	**(1,249.1)**	(3,441.0)
	Net cash flow generated from operating activities (A)	**9,224.9**	12,515.7
2	**CASH FLOW FROM INVESTING ACTIVITIES**		
	Purchase of property, plant and equipment including movement in capital work-in-progress, capital advances and capital creditors	**(1,550.1)**	(3,370.2)
	Proceeds from sale of property, plant and equipment	**6.5**	188.3
	Purchase of non-current investments	**(729.9)**	(10,280.0)
	Proceeds from redemption of debentures	**1,044.8**	5,500.0
	Proceeds from sale of current investments (net)	**7,326.8**	(10.0)
	Proceeds from sale of business to a subsidiary (refer note 4)	**1,432.1**	-
	Dividend received from subsidiaries	**-**	705.6
	Loans given to subsidiaries	**(6,820.0)**	(8,440.0)
	Loans repaid by subsidiaries	**-**	7,301.0
	Interest received	**1,229.4**	1,798.1
	Movement in other bank balances (net)	**0.4**	8.2
	Net cash flow generated from/(used in) investing activities (B)	**1,940.0**	(6,599.0)
3	**CASH FLOW FROM FINANCING ACTIVITIES**		
	Buy back of equity shares (including transaction cost)	**(8,058.0)**	-
	Proceeds from non current borrowings	**-**	1,800.0
	Repayment of non current borrowings	**(5,800.0)**	(1,258.3)
	Proceeds/(repayment) of current borrowings (net)	**2,705.6**	(3,536.5)
	Repayment of lease liabilities	**(120.3)**	(120.1)
	Interest paid	**(897.4)**	(1,174.5)
	Dividend paid	**(0.4)**	(2,321.9)
	Net cash used in financing activities (C)	**(12,170.5)**	(6,611.3)
	Net decrease in cash and cash equivalents (A+B+C)	**(1,005.6)**	(694.6)
	Cash and cash equivalents at the beginning of the year	**1,604.3**	2,952.6
	Effect of exchange differences on cash and cash equivalents	**375.2**	95.1
	Cash and cash equivalents at the end of the year	**973.9**	2,353.1
	Cash and cash equivalents comprises of:		
	Cash on hand	**-**	0.1
	Balance with banks	**973.9**	2,353.0
	Cash and cash equivalents considered for cash flows	**973.9**	2,353.1

DELOITTE HASKINS & SELLS CHARTERED ACCOUNTANTS

AUROBINDO PHARMA LIMITED HYDERABAD

NOTES:

1 The above unaudited standalone financial results of Aurobindo Pharma Limited ("the Company") has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2 The above unaudited standalone financial results of the Company as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on November 04, 2026. The results for the quarter and half year ended September 30, 2026 has been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter and half year ended September 30, 2026.

3 The Company operates in only one reportable segment viz., 'Pharmaceuticals ' in accordance with Ind AS 108, "Operating Segment".

4 The Board of Directors of the Company at its meeting held on April 06, 2026 approved the transfer of domestic branded generic pharmaceutical formulations products business on a going concern basis through a Business Transfer Agreement ("BTA") to Auropharm Limited (previously known as Auro Pharma Limited), a wholly owned subsidiary of the Company on a going concern basis w.e.f April 01, 2026.
Accordingly, disclosure as required under Indian Accounting Standard (Ind AS) 105 "Non-Current Assets Held for Sale and Discontinued Operations", in the standalone financial results for all the periods have been suitably presented.

Particulars	Quarter ended			Half year ended		Year ended
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
Total income	-	-	597.9	-	1,111.3	2,016.8
Total expenses	-	-	609.2	-	1,145.8	2,203.2
Loss before tax	-	-	(11.3)	-	(34.5)	(186.4)
Tax expenses	-	-	(2.6)	-	(8.4)	(44.1)
Loss for the period	-	-	(8.7)	-	(26.1)	(142.3)

Cash flow from discontinued operations	For the half year ended 30.09.2026	For the half year ended 30.09.2025
Cash flow generated from operating activities	-	(35.00)
Cash flow used in investing activities	-	-
Cash flow used in financing activities	-	(0.10)
	-	(35.10)

5 During the year ended March 31, 2026, the Government of India consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Government is in the process of issuing related rules. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations. The Company assessed the implications of the New Labour Codes and recognized an incremental cost of ₹ 173.8 million during the year ended March 31, 2026.

6 The Board of Directors of Company at their meeting held on April 06, 2026, approved buyback of 5,423,728 fully paid-up equity shares of face value of ₹ 1 each (representing 0.93% of the total number of equity shares of the Company) for an aggregate value not exceeding ₹ 8,000.0 million (buyback size) (excluding transaction cost) at a maximum buyback price of ₹ 1,475 per equity share. Upon completion of the buyback, the Company extinguished the equity shares in compliance with applicable rules and regulations. Consequently, the paid-up equity share capital has been reduced by ₹ 5.4 million. The aggregate amount paid for buyback is ₹ 8,058 million including related expenses.

7 The Board of Directors at their meeting held on November 4, 2026 declared an interim dividend of ₹ 7 per equity share (Face value ₹ 1).

DELOITTE HASKINS & SELLS CHARTERED ACCOUNTANTS

By Order of the Board
For Aurobindo Pharma Limited

K.Nithyananda Reddy
Vice Chairman & Managing Director
DIN-01284195

AUROBINDO PHARMA LIMITED HYDERABAD

Place: Hyderabad
Date : November 04, 2026

Deloitte
Haskins & Sells

Chartered Accountants
8th & 9th floors Phase III, Block – M
Meenakshi Pride Rock Survey No. 23,
Gachibowli Serilingampally Municipality
Ranga Reddy District
Hyderabad-500032
Telangana, India

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **AUROBINDO PHARMA LIMITED** ("the Company"), for the quarter and half year ended September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)

C Manish Muralidhar
(Partner)
(Membership No. 213649)
(UDIN: 26213649TRBCUJ6507)

Place: Hyderabad
Date: November 04, 2026

AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)
www.aurobindo.com
Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: info@aurobindo.com

(All amounts are in ₹ million, unless otherwise stated)

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2026	30.06.2026	30.09.2025	**30.09.2026**	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	**Unaudited**	Unaudited	Audited
1	**Revenue from operations**						
	(a) Net sales/ income from operations	**1,02,272.8**	91,058.2	82,369.6	**1,93,331.0**	1,60,287.3	3,33,847.4
	(b) Other operating income	**360.1**	445.3	487.4	**805.4**	1,251.1	2,683.4
	Total revenue from operations	**1,02,632.9**	91,503.5	82,857.0	**1,94,136.4**	1,61,538.4	3,36,530.8
2	**Other income**						
	(a) Foreign exchange gain (net)	**28.5**	526.2	49.8	**554.7**	45.9	-
	(b) Others	**1,653.7**	2,116.1	1,156.1	**3,769.8**	2,209.1	4,920.9
	Total other income	**1,682.2**	2,642.3	1,205.9	**4,324.5**	2,255.0	4,920.9
	Total income (1+2)	**1,04,315.1**	94,145.8	84,062.9	**1,98,460.9**	1,63,793.4	3,41,451.7
3	**Expenses**						
	(a) Cost of materials consumed	**29,802.8**	28,944.0	25,098.0	**58,746.8**	50,449.6	1,03,051.9
	(b) Purchase of stock-in-trade	**9,137.6**	9,317.8	8,460.5	**18,455.4**	16,538.5	34,779.8
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	**893.0**	(1,992.3)	(169.9)	**(1,099.3)**	(1,207.3)	(2,948.1)
	(d) Employee benefits expense	**16,585.5**	14,801.5	12,773.3	**31,387.0**	25,061.3	51,901.7
	(e) Finance costs	**1,022.1**	1,016.6	952.4	**2,038.7**	1,929.9	3,839.7
	(f) Foreign exchange loss (net)	-	-	-	-	-	100.7
	(g) Depreciation, amortisation and impairment expense	**5,311.5**	4,868.2	4,291.9	**10,179.7**	8,348.9	17,781.9
	(h) Other expenses (refer note 11)	**24,656.5**	21,621.9	19,914.1	**46,278.4**	37,881.1	81,187.5
	Total expenses	**87,409.0**	78,577.7	71,320.3	**1,65,986.7**	1,39,002.0	2,89,695.1
4	**Profit before share of profit/(loss) of associates and joint ventures, exceptional items and tax (1+2-3)**	**16,906.1**	15,568.1	12,742.6	**32,474.2**	24,791.4	51,756.6
5	Share of profit/(loss) of associates and joint ventures, net of tax	**(29.4)**	(15.4)	16.6	**(44.7)**	35.8	15.2
6	**Profit before exceptional items and tax (4+5)**	**16,876.7**	15,552.7	12,759.2	**32,429.5**	24,827.2	51,771.8
7	**Exceptional items (refer note 8)**	-	401.8	-	**401.8**		653.3
8	**Profit before tax (6-7)**	**16,876.7**	15,150.9	12,759.2	**32,027.7**	24,827.2	51,118.5
9	**Tax expense**						
	Current tax	**5,085.7**	6,100.1	4,630.3	**11,185.8**	9,537.5	17,361.4
	Deferred tax	**552.6**	(1,269.5)	(352.4)	**(716.9)**	(1,433.6)	(1,272.6)
	Total tax expense	**5,638.3**	4,830.6	4,277.9	**10,468.9**	8,103.9	16,088.8
10	**Profit after tax (8-9)**	**11,238.4**	10,320.3	8,481.3	**21,558.8**	16,723.3	35,029.7
11	Other comprehensive Income						
	A) Items that will not be reclassified subsequently to profit or loss:						
	i) Re-measurement of defined employee benefit liability	**(49.5)**	3.6	(6.1)	**(45.9)**	(28.0)	73.7
	ii) Equity investments through other comprehensive income – net change in fair value	**39.9**	(81.1)	8.8	**(41.2)**	21.1	35.5
	iii) Income-tax relating to items that will not be reclassified to profit or loss	**2.9**	17.5	(0.7)	**20.4**	2.1	(27.0)
	B) Items that will be reclassified subsequently to profit or loss:						
	i) Exchange differences on translating the financial statements of foreign operations	**1,977.5**	(408.7)	5,408.7	**1,568.8**	9,473.9	19,569.8
	ii) Fair value change on derivatives designated as cash flow hedge (net)	**78.0**	-	-	**78.0**		
	iii) Income-tax on items that will be reclassified subsequently to profit or loss	**(19.6)**	-	-	**(19.6)**	-	-
	Total other comprehensive income/(loss) (net of tax)	**2,029.2**	(468.7)	5,410.7	**1,560.5**	9,469.1	19,652.0
12	**Total comprehensive income (net of tax) (10+11)**	**13,267.6**	9,851.6	13,892.0	**23,119.3**	26,192.4	54,681.7
	Attributable to:						
	Owners of the Parent Company	**13,290.0**	9,856.9	13,895.2	**23,147.0**	26,201.1	54,699.4
	Non-controlling interest	**(22.4)**	(5.3)	(3.2)	**(27.7)**	(8.7)	(17.7)
	Out of total comprehensive income above,						
	Profit after tax attributable to:						
	Owners of the Parent Company	**11,260.8**	10,325.6	8,484.5	**21,586.5**	16,732.0	35,047.5
	Non-controlling interest	**(22.4)**	(5.3)	(3.2)	**(27.7)**	(8.7)	(17.8)
	Other comprehensive income/(loss) attributable to:						
	Owners of the Parent Company	**2,029.2**	(468.7)	5,410.7	**1,560.5**	9,469.1	19,651.9
	Non-controlling interest	-	-	-	-		0.1
13	Paid-up equity share capital (face value ₹ 1 per share)	**575.4**	575.4	580.8	**575.4**	580.8	580.8
14	Other equity						3,78,328.9
15	Earnings per equity share (face value ₹ 1 per share)	**(Not annualised)**	(Not annualised)	(Not annualised)	**(Not annualised)**	(Not annualised)	(Annualised)
	(a) Basic (in ₹)	**19.57**	17.86	14.61	**37.52**	28.81	60.34
	(b) Diluted (in ₹)	**19.57**	17.86	14.61	**37.52**	28.81	60.34

DELOITTE HASKINS & SELLS CHARTERED ACCOUNTANTS

AUROBINDO PHARMA LIMITED HYDERABAD

Consolidated Balance Sheet

(All amounts are in ₹ million, unless otherwise stated)

Sl. No.	Particulars	As at 30.09.2026 Unaudited	As at 31.03.2026 Audited
	ASSETS		
1	**Non-current assets**		
	Property, plant and equipment	**1,48,297.6**	1,39,552.0
	Capital work-in-progress	**34,870.6**	30,088.3
	Right-of-use assets	**4,618.4**	3,747.3
	Goodwill	**12,686.2**	8,001.5
	Other intangible assets	**34,046.4**	22,765.0
	Intangible assets under development	**14,505.0**	22,047.3
	Investments accounted for using the equity method	**1,413.4**	1,088.4
	Financial assets		
	Investments	**1,835.5**	1,950.4
	Loans	**72.5**	75.7
	Trade receivables	**0.1**	-
	Other financial assets	**4,271.5**	5,499.0
	Deferred tax assets (net)	**15,588.7**	14,835.9
	Non- current tax assets (net)	**1,912.8**	4,524.3
	Other non-current assets	**3,837.6**	3,758.9
	Total non-current assets	**2,77,956.3**	2,57,934.0
2	**Current assets**		
	Inventories	**1,31,244.2**	1,20,529.4
	Financial assets		
	Investments	**286.5**	7,472.4
	Trade receivables	**75,435.3**	70,943.7
	Cash and cash equivalents	**62,315.1**	71,914.0
	Bank balances other than cash and cash equivalents	**37,177.6**	26,788.9
	Loans	**183.1**	178.7
	Other financial assets	**2,269.0**	1,009.5
	Current tax assets (net)	**200.0**	216.8
	Other current assets	**30,475.8**	28,034.1
	Total current assets	**3,39,586.6**	3,27,087.5
	TOTAL ASSETS (1+2)	**6,17,542.9**	5,85,021.5
	EQUITY AND LIABILITIES		
1	**Equity**		
	Equity share capital	**575.4**	580.8
	Other equity	**3,93,423.6**	3,78,328.9
	Equity attributable to owners of the Parent Company	**3,93,999.0**	3,78,909.7
	Non-controlling interest	**(19.0)**	(81.6)
	Total equity	**3,93,980.0**	3,78,828.1
	Liabilities		
2	**Non-current liabilities**		
	Financial liabilities		
	Borrowings	**9,819.3**	8,027.5
	Lease liabilities	**2,732.3**	2,929.4
	Others	**2,424.6**	2,418.7
	Provisions	**3,769.1**	4,004.1
	Deferred tax liabilities (net)	**3,015.9**	3,060.0
	Other non-current liabilities	**5,130.0**	5,363.6
	Total non-current liabilities	**26,891.2**	25,803.3
3	**Current liabilities**		
	Financial liabilities		
	Borrowings	**72,518.2**	68,734.5
	Lease liabilities	**1,227.9**	1,037.0
	Trade payables		
	total outstanding dues of micro enterprises and small enterprises	**1,563.6**	1,918.8
	total outstanding dues of creditors other than micro enterprises and small enterprises	**57,360.3**	53,753.9
	Other financial liabilities	**47,026.0**	43,046.5
	Other current liabilities	**7,638.7**	6,263.0
	Provisions	**4,398.1**	3,530.4
	Current tax liabilities (net)	**4,938.9**	2,106.0
	Total current liabilities	**1,96,671.7**	1,80,390.1
	TOTAL EQUITY AND LIABILITIES (1+2+3)	**6,17,542.9**	5,85,021.5

DELOITTE HASKINS & SELLS CHARTERED ACCOUNTANTS

AUROBINDO PHARMA LIMITED HYDERABAD

Consolidated Statement of Cash Flows

(All amounts are in ₹ million, unless otherwise stated)

Sl. No.	Particulars	For the half year ended 30.09.2026 Unaudited	For the half year ended 30.09.2025 Unaudited
1	**CASH FLOW FROM OPERATING ACTIVITIES**		
	Net profit before tax	**32,027.7**	24,827.2
	Adjustments for :		
	Depreciation, amortisation and impairment expense	**10,179.7**	8,348.9
	Allowance for expected credit losses (net)	**(1.9)**	72.4
	Liabilities no longer required written back	**(17.1)**	(15.5)
	Unrealised exchange loss/(gain) (net)	**(60.1)**	3,961.4
	Loss/(profit) on sale of property, plant and equipment (net)	**(285.1)**	54.9
	Write-off of intangible assets under development (net)	**1.8**	17.8
	Share of loss/(gain) of associates and joint ventures	**44.7**	(35.8)
	Profit on sale of investments	**(65.0)**	(0.3)
	Dividend income	**(12.8)**	(10.9)
	Finance costs	**1,930.3**	1,853.1
	Interest income	**(2,660.8)**	(1,731.0)
	Operating profit before working capital changes	**41,081.4**	37,342.2
	Movements in working capital:		
	(Increase)/decrease in inventories	**(3,744.5)**	(6,481.7)
	(Increase)/decrease in trade receivables	**949.6**	305.8
	(Increase)/decrease in other financial assets	**2,062.9**	341.3
	(Increase)/decrease in other assets	**(1,686.3)**	(672.6)
	Increase/(decrease) in trade payables	**1,383.9**	5,589.9
	Increase/(decrease) in provision	**583.7**	1,511.7
	Increase/(decrease) in other financial liabilities	**(2,555.3)**	(2,029.2)
	Increase/(decrease) in other liabilities	**490.5**	761.8
	Cash generated from operating activities	**38,565.9**	36,669.2
	Income taxes paid (net of refunds)	**(5,734.5)**	(7,818.6)
	Net cash generated from operating activities (A)	**32,831.4**	28,850.6
2	**CASH FLOW FROM INVESTING ACTIVITIES**		
	Purchase of property, plant and equipment, including movement in capital work- in- progress, capital advances and capital creditors (net)	**(14,301.0)**	(13,631.6)
	Purchase of intangible assets and intangible assets under development	**(2,250.8)**	(2,135.5)
	Proceeds from sale of property, plant and equipment	**565.7**	87.1
	Purchase of non-current investments	**(287.8)**	(120.5)
	Proceeds from sale of non-current investments	**-**	59.1
	Acquisition of subsidiaries, net of cash and cash equivalents acquired	**(20,139.7)**	-
	(Purchase)/proceeds from sale of current investments (net)	**7,251.0**	(10.2)
	Movement in other bank balances	**(10,287.0)**	(8,255.3)
	Dividend received	**12.8**	10.9
	Interest received	**2,414.7**	1,761.9
	Net cash used in investing activities (B)	**(37,022.1)**	(22,234.1)
3	**CASH FLOW FROM FINANCING ACTIVITIES**		
	Buy back of equity shares (including transaction cost)	**(8,058.0)**	-
	Changes in ownership interest in subsidiary not resulting in loss of control	**90.3**	-
	Proceeds from non-current borrowings	**2,318.3**	3,483.4
	Repayment of non-current borrowings	**(6,002.5)**	(6,382.4)
	Proceeds/(repayment) of current borrowings (net)	**8,989.4**	(1,885.7)
	Interest paid	**(1,816.4)**	(1,795.9)
	Repayment of lease liabilities	**(1,477.2)**	(523.4)
	Dividend paid	**(0.4)**	(2,321.9)
	Net cash used in financing activities (C)	**(5,956.5)**	(9,425.9)
	Net decrease in cash and cash equivalents (A + B + C)	**(10,147.2)**	(2,809.4)
	Cash and cash equivalents at the beginning of the year	**71,914.0**	55,637.9
	Effect of exchange differences on cash and cash equivalents	**447.7**	186.2
	Cash and cash equivalents at the end of the year	**62,214.5**	53,014.7
	Cash and cash equivalents comprise of:		
	Cash on hand	**2.7**	1.9
	Balance with banks		
	- in current account	**24,706.2**	22,927.2
	- in money market	**1,310.0**	1,254.6
	- in deposit account	**36,296.2**	29,832.7
	Cash and cash equivalents	**62,315.1**	54,016.4
	Overdraft used for cash and cash management	**100.6**	1,001.7
	Cash and cash equivalents considered for cash flows	**62,214.5**	53,014.7

DELOITTE HASKINS & SELLS CHARTERED ACCOUNTANTS

AUROBINDO PHARMA LIMITED HYDERABAD

NOTES:

1 The above unaudited consolidated financial results of Aurobindo Pharma Limited ("the Company") including its subsidiaries (collectively known as "the Group") and its associates and joint ventures have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2 The above unaudited consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of the Act and Companies (Indian Accounting Standards) Rules, 2015, as amended.

3 The above unaudited consolidated financial results of the Group as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on November 04, 2026. The results for the quarter and half year ended September 30, 2026 has been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified opinion in respect of the limited review for the quarter and half year ended September 30, 2026.

4 The Group operates in only one reportable segment viz., 'Pharmaceuticals ' in accordance with Ind AS 108, "Operating Segment".

5 During the half year ended September 30, 2026:

i) The Company, incorporated a step down subsidiary, Arrow Pharma Production SAS, France through Agile Pharma B.V., Netherlands a wholly owned subsidiary of the Company w.e.f. May 21, 2026.

ii) The Company invested ₹ 5.2 million to acquire 26% stake in Swarnaakshu Solar Power Private Limited, India making it an associate company w.e.f. June 25, 2026.

iii) The Company, incorporated a step down subsidiary, PT Auro Pharm Indonesia through PT Aurogen Pharma Indonesia, a wholly owned subsidiary of the Company w.e.f. July 01, 2026.

iv) The Company, incorporated a subsidiary, Auropharm Overseas Limited w.e.f. Aug 13, 2026.

v) The Company, incorporated a step down subsidiary, A1 Biochem USA INC through A1 Biochem Labs (India) Private Limited, a wholly owned subsidiary of the Company w.e.f. Aug 26, 2026.

vi) The Company, incorporated a step down subsidiary, Avogent Lifesciences Private Limited through Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company w.e.f. Aug 31, 2026.

vii) The Group invested ₹ 165.0 million to acquire stake in Garuda Renewables Private limited, India making it an associate company w.e.f. July 29, 2026.

6 On July 30, 2025, the Company through it's wholly owned subsidiary, Aurobindo Pharma USA, Inc. entered into a definitive agreement to acquire 100% membership interest in Lannett Company LLC.

On June 29, 2026 ('Acquisition date') the Company pursuant to above membership purchase agreement completed the acquisition of 100% membership interest in Lannett Company LLC along with its subsidiaries (Silarx Pharmaceuticals Inc, Kremers Urban Pharmaceuticals Inc and Cody Laboratories Inc) for a purchase consideration of ₹ 23,218.3 million (USD 245.7 million) upon satisfaction of customary closing conditions and receipt of the necessary regulatory approvals and has been consolidated with effect from that date. Hence, the results for the quarter and half year ended September 30, 2026, are not comparable to the earlier periods presented. The transaction was accounted for in accordance with Ind AS 103 (Business Combinations), and the initial accounting has been provisionally determined. The group recognised ₹18,615.7 million (USD 197.0 million) towards the fair value of net assets acquired and ₹ 4,602.7 million (USD 48.7 million) towards Goodwill.

7 The Board of Directors of the Parent Company at its meeting held on April 06, 2026 approved the transfer of domestic branded generic pharmaceutical formulations products business on a going concern basis through a Business Transfer Agreement ("BTA") to Auropharm Limited (previously known as Auro Pharma Limited), a wholly owned subsidiary of the Company on a going concern basis w.e.f April 01, 2026. Accordingly, the net assets of the business have been transferred at the consideration of ₹ 1,432.1 million to Auropharm Limited. Since the transaction is with the wholly owned subsidiary of the Company, there is no impact on the unaudited consolidated financial statements.





NOTES: continued..

8 Exceptional item:

a) For the half year ended September 30, 2026 includes acquisition and related costs of ₹ 401.8 million (USD 4.3 million) in relation to the acquisition of 100% membership interest of Lannett Company LLC.

b) During the year ended March 31, 2026, the Government of India consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Government is in the process of issuing related rules. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations. The Company assessed the implications of the New Labour Codes and recognized an incremental cost of ₹ 653.3 million during the year ended March 31, 2026.

9 The Board of Directors of Parent Company at their meeting held on April 06, 2026, approved buyback of 5,423,728 fully paid-up equity shares of face value of ₹ 1 each (representing 0.93% of the total number of equity shares of the parent company) for an aggregate value not exceeding ₹ 8,000.0 million (buyback size) (excluding transaction cost) at a maximum buyback price of ₹ 1,475 per equity share. Upon completion of the buyback, the parent company extinguished the equity shares in compliance with applicable rules and regulations.
Consequently, the paid-up equity share capital has been reduced by ₹ 5.4 million. The aggregate amount paid for buyback is ₹ 8,058 million including related expenses.

10 During the quarter , Apitoria Pharma Private Limited (a wholly owned subsidiary of the Company), completed the acquisition of A1 Biochem Labs (India) Private Limited ("A1 Biochem Labs") for a consideration of ₹28.5 million. A1 Biochem Labs acquired the business of A1 Biochem Research (India) Private Limited for a consideration of ₹200.0 million on a slump sale basis. Further on August 26, 2026, the Company incorporated A1 Biochem USA Inc. as a step-down subsidiary through A1 Biochem Labs (India) Private Limited. Subsequent to the quarter-end, as on October 1, 2026, A1 Biochem USA Inc acquired Membership Interest in A1 Biochem Labs LLC, USA for a consideration of ₹1,462.1 million.

11 During the half year, Aurobindo Pharma USA, Inc., a wholly owned subsidiary of the Company recorded net loss on derecognition of lease receivable of ₹ 432.6 million (USD 4.5 million) which is included under the head "Other expenses".

12 a. On July 27, 2026, Curateq Biologics Private Limited (wholly owned subsidiary of the Company) submitted the Scheme of Amalgamation by way of merger of Auro Vaccines Private Limited (Transferor Company) with Curateq Biologics Private Limited (Transferee Company) (the 'Applicant Companies') to the National Company Law Tribunal ('NCLT') for approval. Subsequently, on August 18, 2026, the Applicant Companies received an order from the NCLT dispensing with the requirement to convene meetings of their equity shareholders, secured and unsecured creditors, and Compulsorily Convertible Debenture (CCD) holders.

b. On September 18, 2026, Eugia Pharma Specialities Limited (wholly owned subsidiary of the Company) submitted the Scheme of Amalgamation by way of merger of Eugia SEZ Private Limited and Eugia Steriles Private Limited (Transferor Company) with Eugia Pharma Specialities Limited (Transferee Company) (the 'Applicant Companies') to the National Company Law Tribunal ('NCLT') for approval. Subsequently, on October 9, 2026, the Company received an order from the NCLT directing it to convene meetings of its unsecured trade creditors, while dispensing with the requirement to convene a meeting of the Applicant Company's equity shareholders.

Pending regulatory approvals, no impact has been given in the results for the above.

13 The Board of Directors at their meeting held on November 4, 2026 declared an interim dividend of ₹ 7 per equity share (Face value ₹ 1).

By Order of the Board
For Aurobindo Pharma Limited

K.Nithyananda Reddy
Vice Chairman & Managing Director
DIN-01284195

Place: Hyderabad
Date :November 04, 2026

DELOITTE HASKINS & SELLS CHARTERED ACCOUNTANTS

AUROBINDO PHARMA LIMITED HYDERABAD

Deloitte
Haskins & Sells

Chartered Accountants
8th & 9th floors Phase III, Block – M
Meenakshi Pride Rock Survey No. 23,
Gachibowli Serilingampally Municipality
Ranga Reddy District
Hyderabad-500032
Telangana, India

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
AUROBINDO PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **AUROBINDO PHARMA LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss of its associates and joint ventures for the quarter and half year ended September 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of subsidiaries, associates and joint ventures listed in Annexure I.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of 22 subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total assets of ₹ 415,852.6 million as at September 30, 2026, total revenue of ₹ 59,776.9 million and ₹ 117,092.6 million for the quarter and half year ended September 30, 2026 respectively, total net profit after tax of ₹ 1,002.6 million and ₹ 3,289.3 million for the quarter and half year ended September 30, 2026 respectively, total comprehensive income (net) of ₹ 1,001.0 million and ₹ 3,287.7 million for the quarter and half year ended September 30, 2026 respectively and net cash inflows of ₹ 5,163.3 million for the half year ended September 30, 2026, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion on the Statement is not modified in respect of these matters.

7. The unaudited consolidated financial results includes the interim financial information of 65 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total assets of ₹ 114,121.5 million as at September 30, 2026, total revenue of ₹ 25,871.3 million and ₹ 45,920.1 million for the quarter and half year ended September 30, 2026 respectively, total profit after tax (net) of ₹ 558.9 million and ₹ 716.5 million for the quarter and half year ended September 30, 2026 respectively, total comprehensive profit of ₹ 561.1 million and ₹ 718.7 million for the quarter and half year ended September 30, 2026 respectively and net cash inflows of ₹ 1,353.9 million for the half year ended September 30, 2026, as considered in the Statement. The unaudited consolidated financial results also includes the Group's share of loss after tax of ₹ 29.4 million and ₹ 44.7 million for the quarter and half year ended September 30, 2026 respectively and total comprehensive loss of ₹ 29.4 million and ₹ 44.7 million for the quarter and half year ended September 30, 2026 respectively, as considered in the Statement, in respect of 4 associates and 3 joint ventures, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

   Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)

C Manish Muralidhar
Partner
(Membership No. 213649)
(UDIN: 26213649VBODZK9180)

Place: Hyderabad
Date: November 04, 2026

Annexure I to the Independent Auditor's Report on Review of Interim Consolidated Financial Results

The interim unaudited consolidated financial results include results of the following entities:

S No	Name of Component	Country	Relationship
1	Helix Healthcare B.V.	The Netherlands	Direct Subsidiary
2	APL Pharma Thai Limited	Thailand	Direct Subsidiary
3	Aurobindo Pharma Industria Farmaceutica Ltd	Brazil	Direct Subsidiary
4	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Direct Subsidiary
5	All Pharma (Shanghai) Trading Co Ltd	China	Direct Subsidiary
6	Aurobindo Pharma USA Inc.	USA	Direct Subsidiary
7	APL Healthcare Limited	India	Direct Subsidiary
8	Auro Peptides Limited	India	Direct Subsidiary
9	Apitoria Pharma Private Limited	India	Direct Subsidiary
10	Auroactive Pharma Private Limited	India	Direct Subsidiary
11	CuraTeQ Biologics Private Limited	India	Direct Subsidiary
12	AuroZest Private Limited	India	Direct Subsidiary
13	Aurobindo Antibiotics Private Limited	India	Direct Subsidiary
14	Eugia Pharma Specialities Limited	India	Direct Subsidiary
15	GLS Pharma Limited	India	Direct Subsidiary
16	TheraNyM Biologics Private Limited	India	Direct Subsidiary
17	Auropharm Limited (formerly known as Auro Pharma Limited)	India	Direct Subsidiary
18	Aurobindo Pharma Foundation	India	Direct Subsidiary
19	Auro Vaccines Private Limited	India	Step-Down Subsidiary
20	Agile Pharma B.V.	The Netherlands	Step-Down Subsidiary
21	Milpharm Limited	United Kingdom	Step-Down Subsidiary
22	Aurobindo Pharma (Malta) Ltd	Malta	Step-Down Subsidiary
23	APL Swift Services (Malta) Ltd	Malta	Step-Down Subsidiary
24	Aurobindo Pharma (Romania) s.r.l	Romania	Step-Down Subsidiary
25	Pharmacin B.V. (Merged with Agile Pharma B.V. w.e.f July 01, 2025)	The Netherlands	Step-Down Subsidiary
26	Aurovitas Pharma Polska	Poland	Step-Down Subsidiary
27	Generis Farmaceutica S.A.	Portugal	Step-Down Subsidiary
28	Generis Phar, Unipessoal Lda	Portugal	Step-Down Subsidiary
29	Aurobindo Pharma (Italia) S.r.l	Italy	Step-Down Subsidiary
30	Arrow Generiques SAS	France	Step-Down Subsidiary
31	1980 Puren Pharma GmbH, Germany	Germany	Step-Down Subsidiary
32	Puren Pharma GmbH & Co., KG	Germany	Step-Down Subsidiary
33	Aurovitas Spain SA	Spain	Step-Down Subsidiary
34	Aurobindo Pharma B.V.	The Netherlands	Step-Down Subsidiary
35	Aurovitas Spol s.r.o	Czech Republic	Step-Down Subsidiary
36	Apotex Europe B.V.	The Netherlands	Step-Down Subsidiary
37	Aurovitas Nederland B.V	The Netherlands	Step-Down Subsidiary
38	Sameko Farma B.V.	The Netherlands	Step-Down Subsidiary
39	Leidapharm B.V.	The Netherlands	Step-Down Subsidiary
40	Marel B.V.	The Netherlands	Step-Down Subsidiary
41	Pharma Dossier B.V.	The Netherlands	Step-Down Subsidiary
42	Aurobindo NV/SA	Belgium	Step-Down Subsidiary
43	CuraTeQ Biologics s.r.o.	Czech Republic	Step-Down Subsidiary
44	Eugia Pharma B.V.	The Netherlands	Step-Down Subsidiary
45	Eugia Pharma (Malta) Limited	Malta	Step-Down Subsidiary
46	Eugia (UK) Limited	United Kingdom	Step-Down Subsidiary
47	Auro Pharma Inc.	Canada	Step-Down Subsidiary
48	Aurobindo Pharma (Pty) Ltd	South Africa	Step-Down Subsidiary
49	Aurobindo Pharma Japan KK	Japan	Step-Down Subsidiary
50	Aurovida Farmaceutica SA DE CV	Mexico	Step-Down Subsidiary
51	Aurobindo Pharma Colombia S.A.S	Colombia	Step-Down Subsidiary
52	Aurogen South Africa (PTY) Ltd	South Africa	Step-Down Subsidiary
53	Aurobindo Pharma Saudi Arabia Ltd Company	Saudi Arabia	Step-Down Subsidiary
54	Aurovitas Pharma (Taizhou) Ltd	China	Step-Down Subsidiary

S No	Name of Component	Country	Relationship
55	Aurobindo Pharma FZ-LLC	Dubai	Step-Down Subsidiary
56	Aurosalud SA De CV	Mexico	Step-Down Subsidiary
57	Auro PR Inc.	Puerto Rico	Step-Down Subsidiary
58	Eugia Pharma Inc.	Canada	Step-Down Subsidiary
59	Eugia Pharma (Australia) PTY Limited	Australia	Step-Down Subsidiary
60	Eugia Pharma Industria Farmaceutica Limitada	Brazil	Step-Down Subsidiary
61	Aurobindo Pharma Ukraine LLC	Ukraine	Step-Down Subsidiary
62	Eugia Pharma Colombia S.A.S.	Colombia	Step-Down Subsidiary
63	PT Aurogen Pharma	Indonesia	Step-Down Subsidiary
64	Aurolife Pharma LLC	USA	Step-Down Subsidiary
65	Auro Health LLC	USA	Step-Down Subsidiary
66	Auro AR LLC	USA	Step-Down Subsidiary
67	Auro Vaccines LLC	USA	Step-Down Subsidiary
68	AuroLogistics LLC	USA	Step-Down Subsidiary
69	Acrotech Biopharma Inc	USA	Step-Down Subsidiary
70	Auro Science LLC	USA	Step-Down Subsidiary
71	Auro Packaging LLC	USA	Step-Down Subsidiary
72	Vespyr Brands, LLC	USA	Step-Down Subsidiary
73	Eugia Inc.	USA	Step-Down Subsidiary
74	Eugia US LLC	USA	Step-Down Subsidiary
75	Eugia US Manufacturing LLC	USA	Step-Down Subsidiary
76	Eugia Steriles Private Limited	India	Step-Down Subsidiary
77	Lyfius Pharma Private Limited	India	Step-Down Subsidiary
78	Qule Pharma Private Limited	India	Step-Down Subsidiary
79	Eugia SEZ Private Limited	India	Step-Down Subsidiary
80	Auro Pharma LLC	Russia	Step-Down Subsidiary
81	Purple Bellflower, South Africa	South Africa	Step-Down Subsidiary
82	Ace Laboratories Limited	United Kingdom	Step-Down Subsidiary
83	Cresedemo Pharma LLC (w.e.f. June 13, 2025)	USA	Step-Down Subsidiary
84	Curateq Biologics B.V (w.e.f May 28, 2025)	The Netherlands	Step-Down Subsidiary
85	Aurobindo Pharma (Malaysia) SDN. BHD. (w.e.f September 17, 2025)	Malaysia	Step-Down Subsidiary
86	CuraTeQ Biologics (Malta) Limited (w.e.f September 26, 2025)	Malta	Step-Down Subsidiary
87	Aurobindo Pharma Chile SpA (w.e.f October 07, 2025)	Chile	Step-Down Subsidiary
88	Eugia Pharma Chile SpA (w.e.f October 07, 2025)	Chile	Step-Down Subsidiary
89	Aurobindo Pharma Philippines Inc (w.e.f January 23, 2026)	Philippines	Step-Down Subsidiary
90	Diadame Pharma SARL (w.e.f January 1, 2026)	Senegal	Step-Down Subsidiary
91	Engenra Biologics Private Limited (w.e.f February 24, 2026)	India	Direct Subsidiary
92	Arrow Pharma Production SAS (w.e.f. May 21, 2026)	France	Step-Down Subsidiary
93	Lannett Company LLC (w.e.f June 29, 2026)	USA	Step-Down Subsidiary
94	Silarx Pharmaceuticals Inc (w.e.f June 29, 2026)	USA	Step-Down Subsidiary
95	Kremers Urban Pharmaceuticals Inc (w.e.f June 29, 2026)	USA	Step-Down Subsidiary
96	Cody Laboratories Inc (w.e.f June 29, 2026)	USA	Step-Down Subsidiary
97	Auropharm Overseas Limited (w.e.f Aug 13, 2026)	India	Direct subsidiary
98	Avogent Lifesciences Private Limited (w.e.f Aug 31, 2026)	India	Step-Down Subsidiary

S No	Name of Component	Country	Relationship
99	A1 Biochem Labs (India) Private Limited (w.e.f July 23, 2026)	India	Step-Down Subsidiary
100	A1 Biochem USA Inc (w.e.f August 26, 2026)	USA	Step-Down Subsidiary
101	PT Auro Pharm Indonesia (w.e.f July 1, 2026)	Indonesia	Step-Down Subsidiary
102	Luoxin Aurovitas Pharm (Chengdu) Co. Ltd.	China	Joint venture
103	Raidurgam Developers Limited	India	Joint venture
104	Tergene Biotech Limited	India	Joint venture
105	NVNR (Ramannapet I) Power Plant Private Limited	India	Associate
106	NVNR (Ramannapet II) Power Plant Private Limited	India	Associate
107	Swarnaakshu Solar Power Private Limited (w.e.f June 25, 2026)	India	Associate
108	Garuda Renewables Private Limited (w.e.f July 29, 2026)	India	Associate